DJIA 17,813.39 1.20 0.01%
NASDAQ 5,116.14 13.34 0.26%
S&P 500 2,088.87 -0.27 -0.01%
market minute promo

Exelixis (NASDAQ: EXEL)

5.49 -0.01 (-0.18%)

REAL-TIME: Last trade at

Extended Hours: $5.49 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

EXEL $5.49 -0.18%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.49
Previous Close $5.50
Daily Range $5.42 - $5.64
52-Week Range $1.26 - $6.81
Market Cap $1.2B
P/E Ratio -6.04
Dividend (Yield) $0.00 (0.0%)
Volume 2,915,838
Average Daily Volume 3,856,965
Current FY EPS -$0.85




Drug Makers

Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website:

News & Commentary Rss Feed

The FDA Approves Exelixis, Inc's New Cancer Drug

The Swiss are on the offensive against cancer.

Roche & Exelixis Announce Positive Data on Cotellic & Zelboraf

Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination wit

Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress

Did You Miss These Top Stories in Healthcare?

Last week's most exciting healthcare news: Exelixis nets a win, and Colorado takes aim at health insurers.

Exelixis, Inc. Earnings: Riding the Meteor

The biotech is still burning cash, but with data in hand, there's an opportunity for a solid revenue stream shortly.

6 Stocks That Could Double In 2016

If you have some extra cash and want to take a chance, these six stocks have the potential for excellent returns.

Are Investors Nuts To Be Short These Stocks?

Short sellers think shares in these stocks will go lower because catalysts are unlikely to support their lofty valuations.

Exelixis (EXEL) Stock Dropped Following Earnings Release

The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem

Why Exelixis Shares Declined Today

Financial results trump the FDA approval of a key new drug.

See More EXEL News...

EXEL's Top Competitors

EXEL $5.49 (-0.18%)
Current stock: EXEL
TMO $138.66 (0.51%)
Current stock: TMO
ILMN $180.46 (2.37%)
Current stock: ILMN
WAT $133.26 (0.32%)
Current stock: WAT